Brain peptide-containing sustained-release granules, preparation method thereof, brain function improving drink and application

Abstract

The invention provides brain peptide-containing sustained-release granules, a preparation method thereof, a brain function improving drink and application, and relates to the technical field of sustained-release compositions and peptide drinks. According to the beverage, a hydrolyzed brain protein hydrolysate concentrated solution is adopted, and brain peptides are preferably small-molecule peptides, so that the beverage composition can be fully absorbed; in addition, the intestinal peptide is added, and the intestinal peptide can improve the digestion function of intestines and stomach, well protect and repair damaged gastrointestinal mucosa and enhance gastrointestinal motility. Furthermore, brain peptide-containing sustained-release particles are adopted, the stability of the brain peptide-containing sustained-release particles in the storage period is good, and after the brain peptide-containing sustained-release particles are taken, peptide substances and taurine are slowly released, so that gastrointestinal negative is relieved, digestion and absorption are facilitated, and the brain injury rehabilitation speed is increased.

Description

Technical Field

[0001] The present invention relates to the technical fields of sustained-release compositions and peptide beverages, and particularly to brain peptide sustained-release granules, a preparation method thereof, a brain function enhancing beverage, and applications thereof. Background Art

[0002] Brain injury is caused by brain tissue damage resulting from head and facial trauma; typical clinical symptoms commonly include headache, disturbance of consciousness, cranial bleeding, etc., and generally require conservative treatment or surgical treatment. The prognosis of mild cases is relatively good, while severe cases often leave varying degrees of neurological deficits (limb paralysis, slurred speech, sensory disturbance, etc.), and the prognosis is poor.

[0003] The prognosis of traumatic brain injury is closely related to factors such as the severity of the injury, the age, health status of the patient, and timely treatment and rehabilitation measures. Generally speaking, the prognosis of mild traumatic brain injury is relatively optimistic, while that of severe traumatic brain injury is more severe. The prognosis of mild traumatic brain injury is usually good, and patients can often fully recover after receiving appropriate treatment. Mild traumatic brain injury generally manifests as transient loss of consciousness or symptoms such as headache and dizziness after head injury, and usually does not leave obvious sequelae. The prognosis of severe traumatic brain injury is often more complex, and severe traumatic brain injury may cause long-term effects on the patient's physical and cognitive functions. Severe traumatic brain injury patients may experience long-term loss of consciousness, memory loss, language disorders, limb disabilities and other serious sequelae; at this time, the patient may need to receive comprehensive rehabilitation treatment and long-term care.

[0004] Peptides are important components that make up the brain tissue structure and can provide raw materials for the physiological activities and rehabilitation of brain cells.

[0005] Edible peptides need to maintain a certain stability in the complex environment of the gastrointestinal tract to be absorbed smoothly; however, in the strong acidic environment of gastric acid and the action of various enzymes in the gastrointestinal tract, the structure of some peptides will change, and even be over-degraded, decomposed into smaller fragments or amino acids, losing their original structure and function, and unable to be absorbed and utilized in a complete and effective form. Summary of the Invention

[0006] The present invention provides a brain peptide sustained-release granule, a brain function enhancing beverage, and their preparation methods and applications. On the one hand, a brain peptide sustained-release granule and its preparation method are provided. The granule exists stably during the storage period and enters the intestine for sustained release after being taken, reducing the destruction of peptide substances by gastric acid, etc., reducing the gastric irritation of taurine, enabling the peptide substances and taurine to be fully absorbed, better exerting the brain repair effect, and at the same time reducing the gastric digestion burden and being friendly to the gastrointestinal tract. On the other hand, the present application provides a brain function enhancing beverage. The beverage uses the brain peptide sustained-release granule, has good stability, has a good brain repair function, and is easy to digest and absorb. On the other hand, an application of the brain peptide sustained-release granule or the brain function enhancing beverage in foods and / or drugs for treating brain injuries is provided.

[0007] In the first aspect, the present application provides a brain peptide sustained-release granule:

[0008] A brain peptide sustained-release granule, which consists of a core part and a coating layer coated on the core part. It is characterized in that, by mass, the core part includes 10-20 parts of brain protease hydrolysate concentrate, 6-12 parts of walnut peptide, 3-8 parts of intestinal peptide, 2-5 parts of taurine, 4-8 parts of sucrose, and 4-8 parts of povidone; wherein the brain protease hydrolysate contains a short peptide with the sequence Leu-Phe-Leu-Pro-Arg (LFLPR).

[0009] The coating layer includes 7-10 parts of enteric coating material, 2-5 parts of talcum powder, and 0.5-1.5 parts of diethyl phthalate;

[0010] The mass ratio of the coating layer in the brain peptide sustained-release granule is 15-30%.

[0011] Furthermore, the LFLPR short peptide accounts for 0.5-2% of the dry matter content of the brain protease hydrolysate.

[0012] Furthermore, the enteric coating material includes one or at least two combinations of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl alcohol phthalate, and acrylic resin II.

[0013] Furthermore, the coating layer further includes 1-4 parts by mass of gelatin.

[0014] Furthermore, the mass ratio of the enteric coating material to gelatin in the coating layer is (1.38-8.5):1.

[0015] Furthermore, the mass ratio of the enteric coating material to gelatin in the coating layer is (2.17-6.67):1.

[0016] Furthermore, the brain peptide sustained-release granule is 0.5-2.5 mm.

[0017] In a second aspect, the present application provides a method for preparing brain peptide sustained-release granules:

[0018] A method for preparing brain peptide sustained-release granules includes the following preparation steps:

[0019] Prepare an aqueous solution of povidone, and then add the brain protease hydrolysate concentrate to obtain a mixed solution A;

[0020] Mix walnut peptide, intestinal peptide, taurine and sucrose evenly and then mix with the mixed solution A, granulate and size to obtain the core;

[0021] Dissolve the coating material with ethanol to obtain a sustained-release coating solution;

[0022] Apply the sustained-release coating solution to the surface of the core and dry to obtain the brain peptide sustained-release granules.

[0023] In a third aspect, the present application provides a brain function enhancing drink containing brain peptide sustained-release granules:

[0024] A brain function enhancing drink contains the brain peptide sustained-release granules of the present application.

[0025] Furthermore, for the brain function enhancing drink, based on the total mass of the drink composition, it includes 0.5 - 10 wt% of brain protease hydrolysate concentrate; 0.10 - 2 wt% of walnut peptide; 0.03 - 0.12 wt% of intestinal peptide; 2 - 5 wt% of brain peptide sustained-release granules;

[0026] 2 - 5 wt% of erythritol;

[0027] 0.06 - 0.1 wt% of xanthan gum;

[0028] 1 - 7 wt% of concentrated fruit juice;

[0029] 0.3 - 0.5 wt% of wild jujube seed compound powder;

[0030] 0.4 - 0.6 wt% of γ-aminobutyric acid;

[0031] 0.035 - 0.05 wt% of taurine;

[0032] 0.05 - 0.12 wt% of essence;

[0033] 0.015 - 0.021 wt% of nisin;

[0034] 0.003 - 0.009 wt% of sucralose;

[0035] The balance is water.

[0036] In a fourth aspect, the application of a brain peptide sustained-release granule or a brain function enhancing drink of the present application in foods and / or drugs for treating brain injuries.

[0037] Brain peptides can help activate the nervous system, increase the excitability of brain cells, and are helpful for the repair of brain nerves. Peptides have a certain effect on activating the nervous system. Therefore, when there is brain nerve damage, peptides need to be supplemented during the repair process, which helps to accelerate the recovery of nerve function. At the same time, brain peptides are rich in lipids and unsaturated fatty acids, which are important components of the brain. Peptides can promote the repair of brain nerves.

[0038] Enteropeptide concentrate is a biological product with the function of regulating gastrointestinal digestion and absorption, produced by using pig small intestine as raw material and biological extraction technology. Its main components are a mixture of active enteropeptides, amino acids, and enteropolysaccharides (glycosaminoglycans GAGs). The concentration of active substances is higher and the molecular weight is smaller, making it easier to be ingested and absorbed by the human body in large amounts. Enteropeptides can regulate gastrointestinal functions. Vasoactive intestinal peptide belongs to a neurotransmitter and has a dual regulatory role in the body. In the digestive system, it can promote the relaxation of intestinal smooth muscle, and at the same time relax the muscles such as the lower esophageal sphincter and intestinal smooth muscle. In the nervous system, it can dilate blood vessels, increase blood flow, and also dilate the smooth muscle of the trachea and bronchi.

[0039] Walnut peptides can stimulate the growth and elongation of nerve synapses, helping to repair brain nerves. When brain cells carry out physiological activities, they require a certain amount of energy consumption, and walnut peptides can also provide sufficient energy. The combination of brain peptides can better promote the development of brain cells and help repair brain nerves.

[0040] Beneficial effects:

[0041] 1. The present application provides a brain peptide sustained-release granule, which is prepared by using peptide substances and taurine as the core material. The granule exists stably during storage in a water-containing beverage, enters the intestine for slow release, reduces the destruction of peptide substances by gastric acid, etc., reduces the irritation of taurine to the stomach, promotes the full absorption of peptide substances and taurine, exerts the brain repair effect, and at the same time reduces gastric irritation and is easy to digest and absorb.

[0042] 2. Preferably, the coating of the brain peptide sustained-release granule is formulated by combining an enteric coating material and gelatin. The enteric coating material slowly decomposes under the action of digestive enzymes in the intestine, releasing small molecule peptides and taurine active ingredients slowly. An appropriate amount of gelatin is used in the coating layer, so that the coating layer begins to slowly decompose in gastric juice, thereby accelerating the decomposition and release rate of the coating layer in the intestine and enabling the active ingredients to be more fully absorbed by the intestine. At the same time, no highly water-soluble substances are used in the coating layer, so that the brain peptide sustained-release granule can maintain good stability in water.

[0043] 3. The present application provides a brain function enhancing drink. This drink has good stability during the storage period. After being taken, it contains slow-release peptide substances of brain peptide slow-release granules and taurine, which reduces the burden on the gastrointestinal tract, facilitates digestion and absorption, and improves the recovery speed of brain injury. Detailed implementation mode

[0044] To make the technical solution of the present invention clearer, the following further describes the present invention in detail with specific embodiments.

[0045] Preparation Example 1, a brain protease hydrolyzate concentrate, the preparation process is as follows:

[0046] Step 1: Take out fresh pig brains or thawed frozen pig brains, wash them with pure water, and remove fascia and blood vessels; after mixing the pig brains with pure water at a ratio of 1:1.5 by raw materials, grind them into a homogeneous slurry with a colloid mill. After the tissue is basically broken, adjust it to a finer fineness. The grinding and homogenization cycle is 5 min / batch, and then add pure water 1.3 times the amount of the homogenate and continue to homogenize for 5 min. Mix the homogenized brain slurry of each batch evenly, and adjust the pH value to 9.5 with potassium hydroxide solution; the coarsest mesh number is 100 mesh; the finer mesh number is 150 mesh;

[0047] Step 2: Place the adjusted brain slurry homogenate in a microwave tank with a stirring device, control the temperature at 60°C, microwave for 20 min, and keep warm for 15 min; the frequency of the microwave tank is 3300 MHz and the power is 25 KW; discharge the homogenate after microwave treatment, and centrifuge the protein and lipid twice at 38°C with a disc high-speed centrifuge. For the first centrifugation, control the discharged light liquid to be 42%. After discharging the light liquid, microwave for 20 min and then perform the second centrifugation. The light liquid obtained from the second centrifugation is the phospholipid solution. Mix the concentrated liquids obtained from the two centrifugations; the rotation speed of the first centrifugation is 9000 r / min; the rotation speed of the second centrifugation is 12000 r / min; the temperature of the homogenate during the second centrifugation is not lower than 38°C;

[0048] Step 3: Adjust the pH value of the mixed concentrated liquid obtained in Step 2 to 5.0 with dilute hydrochloric acid to make the protein precipitate in a cloud-like large piece and separate layers. Then, dehydrate it with a 250-mesh filter cloth centrifuge, collect the filter residue, and obtain brain separated protein; dissolve the collected filter residue with pure water 2 times the amount of the wet filter residue to obtain a 5% solution, adjust the pH value to 9.0, and then add trypsin (5000 u / g) at 4.5% of the mass of the separated protein and continue to homogenize and circulate; when the pH value drops to about 7.5 again, add alkali to adjust it to 8.6 and circulate for another 3 minutes, and then discharge the slurry;

[0049] Step 4: Feed the slurry obtained in Step 3 into a microwave pre-detection to measure the pH value. When the pH value is less than 7, add alkali to adjust the pH value to 8.2, perform microwave-assisted enzymatic hydrolysis, keep warm for 15 min, and inactivate the enzyme activity; drain the inactivated enzymatic hydrolysate. When the temperature of the enzymatic hydrolysate drops below 40 °C, add a 1.5% chitosan solution dissolved in 15% acetic acid under stirring conditions, adjust the pH value to 4.8, and precipitate unhydrolyzed brain proteins, phospholipids, and other macromolecular impurities; centrifuge and filter the precipitate with a 200-mesh filter cloth to remove the precipitate; filter the centrifugate with a 0.25-μm hollow fiber membrane, and filter the filtrate with an ultrafiltration membrane that can intercept a molecular weight of 10,000 Da. The permeate is the porcine brain polypeptide solution. If only polypeptides are made, this solution is concentrated under reduced pressure and then freeze-dried to obtain polypeptide powder;

[0050] Step 5: Filter the polypeptide solution with a nanofiltration membrane that can intercept a molecular weight of 1200 Da, concentrate the filtrate with a reverse osmosis membrane, freeze the concentrated solution, and dry it to obtain a brain protease hydrolyzate concentrate with a solid content of 55 wt%, and the nitrogen content of the dry matter is 14.5%; the brain protease hydrolyzate concentrate includes a small molecule peptide with the sequence Leu-Phe-Leu-Pro-Arg (LFLPR), and the content of the Leu-Phe-Leu-Pro-Arg (LFLPR) small molecule peptide is 1% of the dry matter.

[0051] LC-MS / MS separation and identification

[0052] Use LC-MS / MS to determine the amino acid sequence and molecular weight of the small molecule peptide components. Before the sample is loaded onto the machine, first perform reduction alkylation and desalting treatment. The pre-column of the capillary liquid chromatography column used is an Acclaim PepMap RPLC C18 analytical column (5 μm) with a size of 300 μm × 5 mm, and the analytical column is an Acclaim PepMap RPLC C18 analytical column (1.9 μm, ) with a size of 150 μm × 150 mm. Mobile phase A is a 0.1% (v / v) formic acid solution and a 2% (v / v) acetonitrile solution, and mobile phase B is a 0.1% (v / v) formic acid solution and an 80% (v / v) acetonitrile solution. The flow rate is 600 nL / min, and the analysis time for each component is 60 min.

[0053] The MS and MS / MS parameters are as follows:

[0054] (1) MS parameters: Resolution is 70,000; maximum injection time is 40 ms; scanning range is 300 - 1400 m / z.

[0055] (2) MS / MS parameters: Resolution is 175,000; maximum injection time is 60 ms; scanning range is 300 - 1400 m / z;

[0056] Top N = 20; NCE / steeped NCE = 27.

[0057] Analyze the original MS / MS files using Mascot software according to the sample type and search and compare with the Uniprot database (https: / / www.uniprot.org / ) Sus scrofa (Pig) to determine the amino acid sequence of the peptide.

[0058] Example 1-1, the preparation of a brain peptide sustained-release granule, using the raw material dosage and types as shown in Table 2, and its process includes the following steps:

[0059] Step 1: Prepare an aqueous solution of polyvinylpyrrolidone with a concentration of 4% by mass, and then add the brain protease hydrolysate concentrate of Preparation Example 1 to obtain a mixed solution A.

[0060] Step 2: Mix walnut peptide, intestinal peptide, taurine and sucrose evenly, place them in a centrifugal granulator, atomize and spray into the mixed solution A, granulate and size the particles to obtain the core.

[0061] In this step, the liquid supply rotation speed can be set to 10 R / M (any value in 9 - 17 R / M in other embodiments), the turntable rotation speed to 60 R / M (any value in 56 - 75 R / M in other embodiments), the fan frequency to 20 Hz (any value in 12 - 26 Hz in other embodiments), and the inlet air temperature to 50 °C (any value in 60 ± 5 °C in other embodiments).

[0062] Step 3: Take the prescribed amount of coating material, dissolve it with 80% ethanol to obtain a sustained-release coating solution.

[0063] Step 4: Place the particle core obtained in Step 2 in a multi-functional fluidized bed, and evenly spray the sustained-release coating solution onto the surface of the core under a fluidized state, and dry at 60 °C to obtain the brain peptide sustained-release granule, with a particle size of about 1 mm (any value in 0.5 - 2.5 mm in other embodiments).

[0064] Table 2. List of raw materials and dosages used in the preparation of brain peptide sustained-release granules in Examples 1-2 to 1-8

[0065]

[0066] Example 1-4, the preparation of a brain peptide sustained-release granule, which is different from Example 1-1 in that the total amount of enteric coating material and gelatin remains unchanged, 9.5 g of cellulose acetate phthalate is used, and gelatin is not used.

[0067] Examples 1-5, Preparation of brain peptide sustained-release granules, which is different from Example 1-1 in that the total amount of enteric coating material and gelatin used remains unchanged, 8.5 g of cellulose acetate phthalate is used, and 1.0 g of gelatin is used; the mass ratio of enteric coating material to gelatin is 8.5:1.

[0068] Examples 1-6, Preparation of brain peptide sustained-release granules, which is different from Example 1-1 in that the total amount of enteric coating material and gelatin used remains unchanged, 7.5 g of cellulose acetate phthalate is used, and 2.0 g of gelatin is used; the mass ratio of enteric coating material to gelatin is 3.75:1.

[0069] Examples 1-7, Preparation of brain peptide sustained-release granules, which is different from Example 1-1 in that the total amount of enteric coating material and gelatin used remains unchanged, 6.5 g of cellulose acetate phthalate is used, and 3.0 g of gelatin is used; the mass ratio of enteric coating material to gelatin is 2.17:1.

[0070] Examples 1-8, Preparation of brain peptide sustained-release granules, which is different from Example 1-1 in that the total amount of enteric coating material and gelatin used remains unchanged, 5.5 g of cellulose acetate phthalate is used, and 4.0 g of gelatin is used; the mass ratio of enteric coating material to gelatin is 1.38:1.

[0071] All raw materials used above are food grade.

[0072] Example 2-1, A brain function enhancing drink, using the raw materials as shown in Table 3, and the preparation process is as follows:

[0073] After mixing the used raw materials, stir at 300 r / min for 40 min at a temperature of 25 °C (in other examples, select any temperature from 15 °C to 30 °C), and a brain function enhancing drink is prepared. (In other examples, select any stirring speed from 200 - 500 r / min and any stirring time from 30 - 50 min).

[0074] The brain protease hydrolyzate concentrate uses the brain protease hydrolyzate concentrate of Preparation Example 1; walnut peptide: walnut small molecule peptide, with a molecular weight less than 1000 Da, solubility > 90%, and moisture < 5%; intestinal peptide: molecular weight less than 1000 Da, solubility > 90%, and moisture < 6%.

[0075] Semen ziziphi spinosae composite powder, 120 mesh, purity 98%; xanthan gum, average molecular weight 2 million, purity 98%, food grade.

[0076] Table 3. List of types and weights of raw materials used in the drinks of Examples 2-1 to 2-3

[0077]

[0078] Examples 2-4 to 2-8, a brain function enhancing drink, which is different from Example 2-1 in that the brain peptide sustained-release granules used are the brain peptide sustained-release granules of Examples 1-4 to 1-8 in sequence.

[0079] Comparative Example 1, a brain function enhancing drink, which is different from Example 2-1 in that no brain peptide sustained-release granules are used.

[0080] Comparative Example 2, a brain function enhancing drink, which is different from Example 2-1 in that the raw materials of the brain peptide sustained-release granules corresponding to the amount used in Example 1-1 in Example 2-1 are not prepared into granules, and the corresponding amount of raw materials is directly added together with other raw materials during the preparation process of the brain function enhancing drink.

[0081] Experimental performance:

[0082] C57 mice (18 - 24 g), male, 10 mice in each group, the dosage used each time is 20 mg / kg, and the drug is administered by gavage after modeling (using Examples and Comparative Examples respectively). The normal group and the control group are gavaged with the same volume of normal saline; once a day for 2 consecutive weeks.

[0083] Preparation of craniocerebral injury model:

[0084] After anesthetizing the mice with chloral hydrate, fix them on the stereotaxic apparatus, shave the hair, cut open the scalp to expose the skull, and make a circular hole with a diameter of 4 mm in the left cerebral hemisphere

[0085] to expose the brain tissue, and use a free fall striker to strike to establish a craniocerebral injury model. In the normal group, the skull is opened without any operation. In the control group, only the brain is struck without administering drugs. In the drug treatment group, the corresponding drug is administered by gavage after the strike; the mice after drug administration are placed on the cage rack, and the cage is lined with filter paper. Observe and record the number of fecal pellets and the quality of feces of the mice every day.

[0086] Measurement of the degree of brain edema:

[0087] After the animals are sacrificed, collect the brain tissue, weigh it, and record it as the wet weight (WW). Then dry the brain tissue in an oven at 110 °C for 24 h, weigh it, and record it as the dry weight (DW). Water content (%) = (WW - DW) / WW × 100%.

[0088] The measurement results of the water content of the brain tissue (mean ± SD) are shown in Table 3.

[0089] Results of behavioral tests:

[0090] The balance fatigue rotarod experiment is to measure the latency time for the mice to fall off the rotating rod, that is,

[0091] Time of persistence on the rotating rod (mean ± SD); The balance beam experiment records the number of missteps of the mice on the balance beam, and this experiment is mainly used to evaluate the sensorimotor ability of animals after injury.

[0092] Determination of inflammation level:

[0093] The levels of inflammatory factors (TNF-α and IL-1β) in the brain tissue were measured using an ELISA enzyme-linked immunosorbent assay kit, and the experimental operations were carried out according to the kit instructions.

[0094] Table 3. Experimental results of Examples 2-1 to 2-8, Comparative Example 1, Comparative Example 2, Normal Group, and Control Group

[0095]

[0096] From Examples 2-1, Comparative Example 1, and Comparative Example 2, it can be seen that the use of the brain peptide sustained-release granules has a good repair effect on the brain nerves. At the same time, because the brain peptide sustained-release granules have a good sustained-release effect, they can better protect the activity of small molecule peptides, do not increase the burden on the spleen and stomach, and have little irritation to the gastrointestinal mucosa.

[0097] From Examples 2-1 to 2-8, it can be seen that in the brain peptide sustained-release granules, an enteric coating material and gelatin are used in combination in the coating layer, and the dosages of both are optimized, so that the brain peptide sustained-release granules have a good sustained-release effect. This may be because the enteric coating material slowly decomposes under the action of digestive enzymes in the intestine, slowly releasing small molecule peptides and taurine active ingredients; the use of an appropriate amount of gelatin in the coating layer causes the coating layer to start to slowly decompose in gastric juice, thereby accelerating the decomposition and release rate of the coating layer in the intestine and making the active ingredients more fully absorbed by the intestine; at the same time, no highly water-soluble substances are used in the coating layer, so that the brain peptide sustained-release granules can maintain good stability in water.

[0098] The above-described embodiments merely represent several implementation manners of the present invention. Their descriptions are relatively specific and detailed, but they should not be construed as limiting the scope of the present invention patent. It should be noted that for those of ordinary skill in the art, without departing from the concept of the present invention, several modifications and improvements can still be made, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the present invention patent shall be subject to the appended claims.

Claims

1. A brain peptide sustained-release granule, characterized in that, It consists of a core part and a coating layer covering the core part. It is characterized in that, by mass parts, the core part includes 10 - 20 parts of cerebroprotease hydrolysate concentrate, 6 - 12 parts of walnut peptide, 3 - 8 parts of intestinal peptide, 2 - 5 parts of taurine, 4 - 8 parts of sucrose, and 4 - 8 parts of povidone; wherein the cerebroprotease hydrolysate contains a short peptide with the sequence Leu - Phe - Leu - Pro - Arg; the coating layer includes 7 - 10 parts of enteric - coating material, 2 - 5 parts of talcum powder, and 0.5 - 1.5 parts of diethyl phthalate; the mass proportion of the coating layer in the brain - peptide sustained - release granules is 15 - 30%.

2. The sustained-release granules containing brain peptides according to claim 1, characterized in that, The enteric - coating material includes one or a combination of at least two of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl alcohol phthalate, and acrylic resin Ⅱ.

3. A brain peptide sustained-release granule according to claim 1, characterized in that, The coating layer further includes 1 - 4 mass parts of gelatin.

4. The brain peptide sustained-release granule according to claim 3, wherein The mass ratio of the enteric - coating material to gelatin in the coating layer is (1.38 - 8.5):

1.

5. A brain peptide sustained-release granule according to claim 4, wherein The mass ratio of the enteric - coating material to gelatin in the coating layer is (2.17 - 6.67):

1.

6. A brain peptide sustained-release granule according to claim 1, characterized in that, The brain - peptide sustained - release granules are 0.5 - 2.5 mm.

7. A preparation method of a brain peptide sustained-release granule according to any one of claims 1-6, characterized in that, It includes the following preparation steps: Prepare an aqueous solution of povidone, and then add the cerebroprotease hydrolysate concentrate to obtain a mixed solution A; Mix walnut peptide, intestinal peptide, taurine, and sucrose evenly and then mix with the mixed solution A, granulate and size - classify to obtain the core part; Dissolve the coating - layer materials with ethanol to obtain a sustained - release coating solution; Apply the sustained - release coating solution onto the surface of the core part and dry to obtain the brain - peptide sustained - release granules.

8. A brain - function - enhancing drink containing the brain - peptide sustained - release granules according to any one of claims 1 - 6.

9. The brain function enhancing drink according to claim 8, wherein, Based on the total mass of the drink composition, it includes 0.5 - 10 wt% of cerebroprotease hydrolysate concentrate; 0.10 - 2 wt% of walnut peptide; 0.03 - 0.12 wt% of intestinal peptide; 2 - 5 wt% of brain - peptide sustained - release granules; 2 - 5 wt% of erythritol; 0.06 - 0.1 wt% of xanthan gum; 1 - 7 wt% of concentrated fruit juice; 0.3 - 0.5 wt% of wild jujube seed composite powder; 0.4 - 0.6 wt% of γ - aminobutyric acid; 0.035 - 0.05 wt% of taurine; 0.05 - 0.12 wt% of essence; 0.015 - 0.021 wt% of nisin; 0.003 - 0.009 wt% of sucralose; the balance is water.

10. Use of a brain - peptide sustained - release granules according to any one of claims 1 - 6 or a brain - function - enhancing drink according to claim 8 or 9 in food and / or medicine for treating brain injury.

Images